Age-Dependent Prognostic Value of KRAS Mutation in Metastatic Colorectal Cancer

Abstract

Background: The age-dependent prognostic impact of KRAS status in metastatic colorectal cancer (mCRC) is unknown. Materials & Methods: We used the National Cancer Database to evaluate the survival by KRAS status for age-groups <50, 50–69 and ≥70, adjusting for relevant patient and tumor characteristics. Results: mCRC patients (n = 26,095; 33.5%) had KRAS status reported, and 11,338 of these patients (43.4%) had mutations in the KRAS gene. Patients with KRAS mutations had worse overall survival than wild-type KRAS patients. In age-groups <50 years (23 vs 29 months; p < 0.001) and 50–69 (21 vs 23.4 months; p < 0.001), KRAS mutations were significantly associated with worse survival, whereas in the ≥70-year age-group, there was no significant association (14 vs 14 months; p = 0.34). Conclusion: We conclude that the age of patients influences the prognostic value of KRAS mutation in metastatic colorectal cancer.

Keywords::

• age of onset
• colorectal neoplasms
• database
• KRAS
• metastasis

Financial & competing interests disclosure

This work was supported by a National Cancer Institute Cancer Center Support Grant to University of Texas Southwestern Medical Center (5P30CA142543-07) to M Beg. The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award no. UL1TR001105. M Beg is Designated Dedman Family Scholar in Clinical Care. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by a National Cancer Institute Cancer Center Support Grant to University of Texas Southwestern Medical Center (5P30CA142543-07) to M Beg. The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award no. UL1TR001105. M Beg is Designated Dedman Family Scholar in Clinical Care. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.